Trial | NCT00305474  Report issue

Official Title

Identification and Treatment of the Liability to Develop Schizophrenia

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    100
This study seeks to determine whether adult, non-psychotic, first-degree relatives of schizophrenic patients who show specific neurocognitive deficits and negative symptoms will show improvements in these areas following a 6-month, double-blind trial of a low dose (up to 2.0 mg) of risperidone.
Study Started
Dec 31
2003
Primary Completion
Jan 31
2010
Anticipated
Last Update
Jun 24
2009
Estimate

Drug Risperidone

Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients

Criteria 

Inclusion Criteria:

Having at least one first-degree biological relative with schizophrenia and their age is between 19 and 59.
Desire to participate in a medication trial.
Is able to provide informed consent.
Having moderate levels of negative symptoms, defined as 6 items rated 3 or higher on the Scale for the Assessment of Negative Symptoms (SANS).
Scoring two or more standard deviations below normal in at least one of three cognitive domains: vigilance/working memory, long-term verbal memory, and executive functions.
Scoring at least one standard deviation below normal in a second cognitive domain.

Exclusion Criteria:

IQ less than 80.
Formal education less than 10 years.
History of psychotic disorders.
History of treatment with an antipsychotic medication.
A substance abuse diagnosis within 6 months of diagnosis.
A head injury with documented loss of consciousness exceeding 5 minutes (or subsequent cognitive deficits).
A history of neurologic disease or damage.
A medical condition with significant cognitive sequelae.
A history of electroconvulsive treatment.
No Results Posted